Search results
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival
Barrons.com· 11 hours agoSECTORFOCUS BLOG A second failure of a late-stage trial testing a gene therapy to treat Duchenne ...
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Investor's Business Daily· 9 hours agoSarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy...
Sarepta’s stock gains after Pfizer’s Duchenne trial failure - Boston Business Journal
The Business Journals· 14 hours agoSarepta Therapeutics, a Cambridge drugmaker known for its Duchenne muscular dystrophy treatments,...
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with ...
Morningstar· 1 day ago(NYSE: PFE) today announced that CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational mini-dystrophin gene therapy, fordadistrogene ...
Sarepta shares rise as Pfizer DMD trial misses goals By Investing.com
Investing.com· 13 hours agoThe firm's stance comes after Pfizer (NYSE:PFE) announced its phase 3 trial for a gene therapy...
Pfizer’s Phase III DMD gene therapy trial misses primary endpoint
Clinical Trials Arena via Yahoo Finance· 20 hours agoPfizer has reported that its Phase III CIFFREO clinical trial of investigational mini-dystrophin...
Pfizer’s gene-therapy trial failure boosts Sarepta’s stock
Market Watch· 16 hours agogained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a...
Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision
BioPharma Dive via Yahoo Finance· 18 hours agoThe failure of another trial adds to uncertainty around the benefits of the gene-based treatments,...
Pfizer gene therapy for Duchenne fails to meet goals of key trial
BioPharma Dive via Yahoo Finance· 1 day agoThe negative results from the Phase 3 study, called Ciffreo, come a little more than a month after...
Health Care Roundup: Market Talk
The Wall Street Journal· 12 hours agoPublished exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 0748 ET – The failure of Pfizer’s proposed gene therapy for Duchenne ...